# Seer Board of Directors Issues Letter to Shareholders Highlighting the Company’s Significant Scientific Progress and Addressing Radoff and Torok’s Short-Sighted Campaign
Canonical URL: https://biopharmsignal.com/news/SEER/seer-board-of-directors-issues-letter-to-shareholders-highlighting-the-company-s-significant-scientific-progress-and-addressing-radoff-and-torok-s-short-sighted-campaign
Ticker: SEER
Company: Seer, Inc
Source: Seer, Inc
Published: 2026-06-25 13:46 EST
Original Source URL: https://investor.seer.bio
## Summary

Urges Stockholders to Vote “FOR” ONLY Seer’s Director Nominees on the BLUE Proxy Card REDWOOD CITY, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”) today issued a letter to stockholders containing important information for shareholders to consider in

## Article Body
Urges Stockholders to Vote “FOR” ONLY Seer’s Director Nominees on the BLUE Proxy Card REDWOOD CITY, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”) today issued a letter to stockholders containing important information for shareholders to consider in
## Recent Company News
- 2026-07-06 11:00 EST — [Seer Files Investor Presentation Highlighting Strong Momentum, Commercial Opportunity and Significant Long-Term Value Creation Potential](https://biopharmsignal.com/news/SEER/seer-files-investor-presentation-highlighting-strong-momentum-commercial-opportu-e67fff29) — Source: Seer, Inc
- 2026-07-02 21:00 EST — [Seer Announces Receipt of Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.](https://biopharmsignal.com/news/SEER/seer-announces-receipt-of-unsolicited-acquisition-proposal-from-omid-farokhzad-m-c91bb35c) — Source: Seer, Inc
- 2026-07-01 11:00 EST — [Seer Prevails in European Patent Opposition as U.S. ITC Opens Investigation into Nanomics](https://biopharmsignal.com/news/SEER/seer-prevails-in-european-patent-opposition-as-u-s-itc-opens-investigation-into--47d79284) — Source: Seer, Inc
- 2026-06-25 13:46 EST — [Seer and Korea University Present Preliminary Data at ASMS 2026 Demonstrating Potential of AI-Driven Plasma Proteomics for Multi-Cancer Screening](https://biopharmsignal.com/news/SEER/seer-and-korea-university-present-preliminary-data-at-asms-2026-demonstrating-potential-of-ai-driven-plasma-proteomics-for-multi-cancer-screening) — Source: Seer, Inc
- 2026-06-25 13:46 EST — [Seer Board of Directors Issues Letter to Shareholders Highlighting the Company’s Significant Scientific Progress and Addressing Radoff and Torok’s Short-Sighted Campaign](https://biopharmsignal.com/news/SEER/seer-board-of-directors-issues-letter-to-shareholders-highlighting-the-company-s-significant-scientific-progress-and-addressing-radoff-and-torok-s-short-sighted-campaign) — Source: Seer, Inc
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)